We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Our extensive experience with liposome science allows us to combine onset speed and benefit duration, and to improve API concentrations at target tissues while decreasing unwanted systemic exposures.
Our BioSeizerÂŽ lipid formulation technology enables both local sustained release and fast onset of APIs at the site of disease or injury with increased pharmacokinetic (PK) control, made possible by customization of lipid layers. BioSeizerÂŽ is utilized in our TLC599, TLC399 and TLC590 programs.
Our NanoX⢠active drug loading technology enables better toxicity profiles, potential for reduced dosing frequency, and enhanced distribution of liposome-encapsulated APIs to the desired site. NanoX⢠is capable of loading over 50 various compounds and is applied to our TLC178 program.
Source
